Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells

Journal of the National Cancer Institute

Volumn 90, Issue 2, 1998, Pages 124-133

  Shao, Wenlin ^a   Fanelli, Mirco ^c,g   Ferrara, Fabiana F ^b   Riccioni, Roberta ^b   Rosenauer, Angelika ^a   Davison, Kelly ^a   Lamph, William W ^e   Waxman, Samuel ^f   Pelicci, Pier Giuseppe ^c   Lo Coco, Francesco ^b   Avvisati, Giuseppe ^b   Testa, Ugo ^d   Peschle, Cesare ^d   Gambacorti Passerini, Carlo ^g   Nervi, Clara ^b   Miller Jr , Wilson H ^a,h  

^a MCGILL UNIVERSITY   (Canada)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e LIGAND PHARMACEUTICALS INC   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h 3755 Ch de la Cote Ste Catherine ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYTOTOXIC AGENT; HYBRID PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIGAND BINDING;

EID: 0000531696     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.2.124     Document Type: Article

References (51)

1. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83:10-25.
2. Degos L, Dombret H, Chomienne C, Daniel MT, Miclea JM, Chastang C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995;85:2643-53.
3. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385-93.
4. Miller WH Jr, Warrell RP Jr, Frankel SR, Jakubowski A, Gabrilove JL, Muindi J, et al. Novel retinoic acid receptor-α transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid. J Natl Cancer Inst 1990;82:1932-3.
5. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, et al. Structure and origin of the acute promyelocytic leukemia myl/RARα cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 1991;6:1285-92.
6. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15:17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991;66:675-84.
7. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VV, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991;66:663-74.
8. Kastner P, Perez A, Lutz Y, Rochette-Egly C, Gaub MP, Durand B, et al. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J 1992;11:629-42.
9. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, et al. The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells, Cell 1993;74:423-31.
10. Grignani F, Testa U, Fagioli M, Barberi T, Masciulli R, Mariani G, et al. Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells. Cancer Res 1995;55:440-3.
11. Daniel MT, Koken M, Romagne O, Barbey S, Bazarbachi A, Stadler M, et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 1993;82:1858-67.
12. Dyck JA, Maul GG, Miller WH Jr, Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994;76:333-43.
13. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, et al, Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell 1994;76:345-56.
14. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, et al. PML/RARα oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 1996;88:2826-32.
15. Yoshida H, Kitamura K, Tanaka K, Omura S, Miyazaki T, Hachiya T, et al. Accelerated degradation of PML-retinoic acid receptorα (PML-RARα) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res 1996;56:2945-8.
16. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, et al. All-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704-9.
17. Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, et al. A clinical and experimental study on all-trans-acid treated acute promyelocytic leukemia patients. Blood 1991;78:1413-9.
18. Duprez E, Ruchaud S, Houge G, Martin-Thouvenin V, Valensi F, Kastner P, et al. A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features. Leukemia 1992;6:1281-7.
19. Dermime S, Grignani F, Clerici M, Nervi C, Sozzi G, Talamo GP, et al. Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RARα protein. Blood 1993;82:1573-7.
20. Rosenauer A, Raelson JV, Nervi C, Eydoux P, DeBlasio A, Miller WH Jr. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wildtype retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood 1996;88:2671-82.
21. Chen G, Zhu J, Shi X, Ni J, Zhong H, Si G, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996;88:1052-61.
22. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89: 3354-60.
23. Fu S, Consoli U, Hanania EG, Zu Z, Claxton DF, Andreeff M, et al. PML/RAR, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells. Clin Cancer Res 1995;1:583-90.
24. Rogaia D, Grignani F, Grignani F, Nicoletti I, Pelicci PG. The acute promyelocytic leukemia-specific PML/RARα fusion protein reduces the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF-dependent myeloid cells. Leukemia 1995;9:1467-72.
25. Nervi C, Poindexter EC, Grignani F, Pandolfi PP, Lo Coco F, Avvisati G, et al. Characterization of the PML-RARα chimeric product of the acute promyelocytic leukemia-specific t(15;17) translocation. Cancer Res 1992; 52:3687-92.
26. Miller WH Jr, Jakubowski A, Tong WP, Miller VA, Rigas JR, Benedetti F, et al. 9-cis Retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 1995;85:3021-7.
27. Nervi C, Grippo JF, Sherman MI, George MD, Jetten AM. Identification and characterization of nuclear receptor acid-binding activity in human myeloblastic leukemia HL-60 cells. Proc Natl Acad Sci U S A 1989;86: 5854-8.
28. Rochette-Egly C, Oulad-Abdelghani M, Staub A, Pfister V, Scheuer I, Chambon P, et al. Phosphorylation of the retinoic acid receptor-alpha by protein kinase A. Mol Endocrinol 1995;9:860-71.
29. Flenghi L, Fagioli M, Tomassoni L, Pileri S, Gambacorta M, Pacini R, et al. Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia. Blood 1995;85:1871-80.
30. Chirgwin JM, Przybyla AF, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979;18:5294-9.
31. Zinn K, DiMaio D, Maniatis T. Identification of two distinct regulatory regions adjacent to the human β-interferon gene. Cell 1984;34:865-79.
32. Melton D, Krieg P, Rebacylilati M, Maniatis T, Zinn K, Green, M. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing SP6 promoters. Nucleic Acids Res 1984; 12:7035-56.
33. Jetten AM, Shirley JE. Characterization of transglutaminase activity in rabbit tracheal epithelial cells. Regulation by retinoids. J Biol Chem 1986; 261:15097-101.
34. Lanotte M, Martin-Thouvenin V, Najman S, Ballerini P, Valensi F, Bergen R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991;77:1080-6.
35. Perez A, Kastner P, Sethi S, Lutz Y, Reibel C, Chambon P. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J 1993;12:3171-82.
36. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR mutation. Blood 1997;89:4282-9.
37. Drach J, Zhao S, Malavasi F, Mehta K. Rapid induction of CD38 antigen on myeloid leukemia cells by all trans-retinoid acid. Biochem Biophys Res Commun 1993;195:545-50.
38. Drach J, McQueen T, Engel H, Andreeff M, Robertson KA, Collins SJ, et al. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-α. Cancer Res 1994;54:1746-52.
39. Benedetti L, Grignani F, Scicchitano BM, Jetten AM, Diverio D, Lo Coco F, et al. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARα-mediated increase of type II transglutaminase. Blood 1996;87:1939-50.
40. Nielson FH, Uthus EO. Biochemistry of the essential ultratrace elements. New York (NY): Plenum Press, 1981:319.
41. Dong JT, Luo XM. Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts. Mutat Res 1994;315:11-5.
42. Lee TC, Oshimura M, Barrett JC. Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis 1985;6:1421-6.
43. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of As203 in the treatment of acute promyelocytic leukemia (APL): I. As203 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-53.
44. Altabef M, Garcia M, Lavau C, Bae S, Dejean A, Samarut J. A retrovirus carrying the promyelocyte-retinoic acid receptor PML-RARα fusion gene transforms haematopoietic progenitors in vitro and induces acute leukaemias. EMBO J 1996;15:2707-16.
45. Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol 1994; 14:6858-67.
46. Koken MH, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix MK, Sobczak-Thepot J, et al. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 1995;10:1315-24.
47. Houle B, Rochette-Egly C, Bradley WE. Tumor-suppressive effect of the retinoic acid receptor β in human epidermoid lung cancer cells. Proc Natl Acad Sci U S A 1993;90:985-9.
48. Li XS, Shao ZM, Sheikh MS, Eiseman JL, Sentz D, Jetten AM, et al. Retinoic acid nuclear receptor beta inhibits breast cancer anchorage independent growth. J Cell Physiol 1995;165:449-58.
49. Si SP, Lee X, Tsou HC, Buchsbaum R, Tibaduiza E, Peacocke M. RARβ 2-mediated growth inhibition in HeLa cells. Exp Cell Res 1996;223: 102-11.
50. Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, et al. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst 1997;89:624-9.
51. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997;94:3978-83.